Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Isavuconazonium Sulfate

FDA-approved product (capsule, oral), marketed as Cresemba.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Isavuconazonium Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Mucormycosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC05

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Isavuconazonium Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Isavuconazonium Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics of Isavuconazole in Patients in the Intensive Care Unit

    NCT04777058 · start 2021-03-01

    Registered record
    Registry ID
    NCT04777058
    Conditions
    Invasive Fungal Infections; Pharmacokinetics; Intensive Care Unit
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2022-09-29
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections; Pharmacokinetics; Intensive Care Unit
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial

    NCT04680884 · start 2020-12-21

    Registered record
    Registry ID
    NCT04680884
    Conditions
    Acute Respiratory Failure; Immunocompromised Patients
    Interventions
    Experimental for steroid; Experimental for antifungals; Experimental for steroids and antifungals; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-12-21
    Completion
    2023-12-21
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Failure; Immunocompromised Patients
    InterventionExperimental for steroid; Experimental for antifungals; Experimental for steroids and antifungals; Standard of care
    PhasePhase 3
    Registry statusUnknown

  • A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

    NCT05140096 · start 2020-01-03

    Registered record
    Registry ID
    NCT05140096
    Conditions
    Healthy Volunteers
    Interventions
    Acalabrutinib; Fluconazole; Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-03
    Completion
    2020-04-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAcalabrutinib; Fluconazole; Isavuconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    NCT04065399 · start 2019-11-05

    Registered record
    Registry ID
    NCT04065399
    Conditions
    Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Lineage Acute Leukemia; Mixed Phenotype Acute Leukemia; Acute Leukemia of Ambiguous Lineage
    Interventions
    revumenib; cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2019-11-05
    Completion
    2027-12-15
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Lineage Acute Leukemia; Mixed Phenotype Acute Leukemia +1 more
    Interventionrevumenib; cobicistat
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

    NCT03816176 · start 2019-08-22

    Registered record
    Registry ID
    NCT03816176
    Conditions
    Invasive Mucormycosis; Invasive Aspergillosis
    Interventions
    Isavuconazonium sulfate; Isavuconazonium sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-08-22
    Completion
    2022-12-14
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Mucormycosis; Invasive Aspergillosis
    InterventionIsavuconazonium sulfate; Isavuconazonium sulfate
    PhasePhase 2
    Registry statusCompleted

  • Study to Optimize the Use of New Antibiotics

    NCT03941951 · start 2019-07-09

    Registered record
    Registry ID
    NCT03941951
    Conditions
    Bacterial Infections; Fungal Infection
    Interventions
    Non-impositive Program for Optimizing the Use of Antimicrobials
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-07-09
    Completion
    2022-12-31
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections; Fungal Infection
    InterventionNon-impositive Program for Optimizing the Use of Antimicrobials
    PhaseNot applicable
    Registry statusUnknown

  • Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

    NCT03964090 · start 2019-06-27

    Registered record
    Registry ID
    NCT03964090
    Conditions
    Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma
    Interventions
    TEDD-R; TEDDI-R; Ibrutinib; Cytarabine; Isavuconazole; Methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-06-27
    Completion
    2029-12-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Nervous System Lymphoma; Secondary Central Nervous System Lymphoma
    InterventionTEDD-R; TEDDI-R; Ibrutinib; Cytarabine +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

    NCT03471988 · start 2018-04-16

    Registered record
    Registry ID
    NCT03471988
    Conditions
    Deep Mycosis
    Interventions
    AK1820; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-04-16
    Completion
    2021-04-21
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep Mycosis
    InterventionAK1820; Voriconazole
    PhasePhase 3
    Registry statusCompleted

  • VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

    NCT03327727 · start 2018-02-20

    Registered record
    Registry ID
    NCT03327727
    Conditions
    Invasive Aspergillosis; Invasive Pulmonary Aspergillosis
    Interventions
    Investigational Agent: VL-2397; Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-02-20
    Completion
    2019-01-14
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis; Invasive Pulmonary Aspergillosis
    InterventionInvestigational Agent: VL-2397; Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
    PhasePhase 2
    Registry statusTerminated

  • A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

    NCT03241550 · start 2017-10-02

    Registered record
    Registry ID
    NCT03241550
    Conditions
    Hematological Malignancy
    Interventions
    isavuconazonium sulfate - intravenous; isavuconazonium sulfate - oral
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-02
    Completion
    2019-07-05
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancy
    Interventionisavuconazonium sulfate - intravenous; isavuconazonium sulfate - oral
    PhasePhase 1
    Registry statusCompleted

  • Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

    NCT03149055 · start 2017-05-04

    Registered record
    Registry ID
    NCT03149055
    Conditions
    Hematologic Malignancy; Myeloproliferative Disorder
    Interventions
    Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-05-04
    Completion
    2021-11-08
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancy; Myeloproliferative Disorder
    InterventionIsavuconazole
    PhasePhase 2
    Registry statusCompleted

  • Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia

    NCT03019939 · start 2017-03-28

    Registered record
    Registry ID
    NCT03019939
    Conditions
    Acute Myeloid Leukemia; Myelodysplastic Syndrome; Neutropenia
    Interventions
    Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-28
    Completion
    2020-08-10
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Myelodysplastic Syndrome; Neutropenia
    InterventionIsavuconazole
    PhasePhase 2
    Registry statusCompleted

  • Registry of Patients Treated With Systemic Mold-Active Triazoles

    NCT03066011 · start 2017-03-16

    Registered record
    Registry ID
    NCT03066011
    Conditions
    Invasive Fungal Infection
    Interventions
    Isavuconazonium sulfate; Voriconazole; Posaconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-03-16
    Completion
    2020-04-24
    Enrolment
    2,015

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infection
    InterventionIsavuconazonium sulfate; Voriconazole; Posaconazole
    PhaseNot recorded
    Registry statusCompleted

  • Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    NCT03013998 · start 2016-11

    Registered record
    Registry ID
    NCT03013998
    Conditions
    Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
    Interventions
    Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2); Laboratory Biomarker Analysis; Daunorubicin (BAML-16-001-S1); Cytarabine (BAML-16-001-S1); Azacitidine (BAML-16-001-S2); AG-221 (BAML-16-001-S3); Azacitidine (BAML-16-001-S3); Entospletinib (BAML-16-001-S4); Azacitidine (BAML-16-001-S4); Entospletinib (BAML-16-001-S5); Decitabine (BAML-16-001-S5); Entospletinib (BAML-16-001-S6); Daunorubicin (BAML-16-001-S6); Cytarabine (BAML-16-001-S6); Pevonedistat (BAML-16-001-S9); Azacitidine (BAML-16-001-S9); AG-120 (BAML-16-001-S16); Azacitidine (BAML-16-001-S16); Gilteritinib (BAML-16-001-S8 Group 1); Decitabine (BAML-16-001-S8 Group 1); AZD5153 (BAML-16-001-S10); Venetoclax (BAML-16-001-S10); TP-0903 (BAML-16-001-S14); Decitabine (BAML-16-001-S14); Decitabine (BAML-16-001-S8 Group 2); Venetoclax (BAML-16-001-S8 Group 2); AZD5991 (BAML-16-001-S18); Azacitidine (BAML-16-001-S18); SNDX-5613 (BAML-16-001-S17); Azacitidine (BAML-16-001-S17); Venetoclax (BAML-16-001-S17); Gilteritinib (BAML-16
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2016-11
    Completion
    2032-12
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreviously Untreated Relapsed Refractory Acute Myeloid Leukemia
    InterventionSamalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2); Laboratory Biomarker Analysis; Daunorubicin (BAML-16-001-S1) +29 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

    NCT02128893 · start 2014-01

    Registered record
    Registry ID
    NCT02128893
    Conditions
    Pharmacokinetics of Isavuconazole; Healthy Subjects
    Interventions
    Isavuconazole; Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-01
    Completion
    2014-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics of Isavuconazole; Healthy Subjects
    InterventionIsavuconazole; Esomeprazole
    PhasePhase 1
    Registry statusCompleted